Brief: Immunogen Announces Results From The Phase 3 Mirasol Trial Selected As Late-Breaking Presentation For Asco 2023 Annual Meeting
09/05/2023 11:31
May 9 (Reuters) - ImmunoGen Inc IMGN.O :
* IMMUNOGEN ANNOUNCES RESULTS FROM THE PHASE 3 MIRASOL TRIAL
SELECTED AS LATE-BREAKING PRESENTATION FOR ASCO 2023 ANNUAL
MEETING
Source text for Eikon: ID:nBwPjbs1a
Further company coverage: IMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmunoGen
See all newsBrief: Abbvie Completes Acquisition Of Immunogen
Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77
Brief: Immunogen Says German Federal Cartel Office Approved Merger With Abbvie Unconditionally
Ambrx Biopharma surges on J&J's buyout announcement
Street View: BioMarin-Elliott settlement likely eases investor frustration